Moderna, Inc. has rallied nearly 60% year-to-date, aided by clinical data, confirmation of potential 2026 clinical readouts, and financial updates. MRNA's updated five-year phase 2b data for ...

Jan 30 (Reuters) - Moderna's (MRNA.O), opens new tab Chief Medical Officer Jacqueline Miller, who led the development of the company's mRNA-based COVID-19 vaccine Spikevax, will step down effective ...

Moderna Chief Medical Officer Jacqueline Miller, M.D., is stepping down after a little more than a year in the role. As of publication, Moderna has not responded to Fierce Biotech’s questions about a ...

Moderna has out-licensed a rare disease drug candidate to Recordati, accepting $50 million upfront for an asset that could deliver registrational data this year. Recordati, an Italian company that ...

Moderna will continue to lead clinical development and manufacturing of the asset, while Recordati will handle commercialization of mRNA-3927, which is under development for the rare metabolic ...

Some Florida pharmacies are making the measles vaccine readily available following three new cases of the disease reported in ...

The American Academy of Family Physicians (AAFP) split with federal health officials and recommended that all U.S. adults get an updated COVID-19 vaccine for the upcoming respiratory virus season. In ...

Moderna's and Merck's partnership could help to advance cancer care. A promising skin cancer trial might have broader implications for other types of tumor treatments. Five-year follow-up data from a ...

In a small clinical trial, customized mRNA vaccines against high-risk skin cancers appeared to reduce the risk of cancer recurrence and death by nearly 50 percent over five years when compared with ...